Across TCGA pan-cancer cohorts, DYNLT3 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated DYNLT3 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher DYNLT3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DYNLT3 expression acts as an unfavorable survival marker.
ESCA are the cancer types where DYNLT3 Mutation most reproducibly stratifies survival.